Mihai D. Azimioara is currently Senior Staff Scientist in the chemistry department at 1859, Inc. He has more than 25 years of experience in drug discovery.
He received his BSc from California Institute of Technology in 1989 and MA from Harvard University in 1996. After spending a number of years in expanding his drug discovery expertise at Biogen, ARIAD Pharmaceuticals, Tanabe Research Labs, Arena Pharmaceuticals and Ambit, he worked 15 years at Novartis (GNF) in San Diego helping to bring to preclinical stage a number of projects for treatment of diabetes, cancer, auto-immune diseases and cystic fibrosis. Since leaving Novartis, Mihai has worked first with Plexium, and currently with 1859, Inc. in developing technology platforms that could speed up and expand the drug-discovery process, including addressing biological targets that have proven difficult to address.
Mihai is a coauthor of over 25 patents and almost 20 peer-reviewed articles.